These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 8388358

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
    Sassi M, Chakroun T, Mbemba E, Van Dreden P, Elalamy I, Larsen AK, Gerotziafas GT.
    Clin Appl Thromb Hemost; 2017 Mar; 23(2):155-163. PubMed ID: 27609342
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit.
    Carrie D, Caranobe C, Boneu B.
    Br J Haematol; 1993 Apr; 83(4):622-6. PubMed ID: 8390849
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM, Bara L, Gerotziafas GT.
    Haemostasis; 1994 Apr; 24(2):105-17. PubMed ID: 7959358
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE, Thomas DP.
    Thromb Haemost; 1987 Oct 28; 58(3):839-42. PubMed ID: 3433248
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Involvement of the extrinsic pathway in the activities of low molecular weight heparins.
    Norrheim L, Abildgaard U, Larsen ML, Lindahl AK.
    Thromb Res Suppl; 1991 Oct 28; 14():19-27. PubMed ID: 1658967
    [Abstract] [Full Text] [Related]

  • 11. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy.
    Béguin S, Welzel D, Al Dieri R, Hemker HC.
    Haemostasis; 1999 Oct 28; 29(2-3):170-8. PubMed ID: 10629396
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
    Volovyk Z, Monroe DM, Qi Y, Becker R, Hoffman M.
    J Thromb Thrombolysis; 2009 Aug 28; 28(2):132-9. PubMed ID: 19543696
    [Abstract] [Full Text] [Related]

  • 15. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
    Ammollo CT, Semeraro N, Carratù MR, Colucci M, Semeraro F.
    J Pharmacol Exp Ther; 2016 Feb 28; 356(2):305-13. PubMed ID: 26578266
    [Abstract] [Full Text] [Related]

  • 16. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides.
    Raake W, Klauser RJ, Elling H, Meinetsberger E.
    Thromb Res; 1989 Dec 15; 56(6):719-30. PubMed ID: 2561233
    [Abstract] [Full Text] [Related]

  • 17. An update on heparins at the beginning of the new millennium.
    Fareed J, Hoppensteadt DA, Bick RL.
    Semin Thromb Hemost; 2000 Dec 15; 26 Suppl 1():5-21. PubMed ID: 11011802
    [Abstract] [Full Text] [Related]

  • 18. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA, Smith LM, Anvari N, Blajchman MA.
    Thromb Haemost; 1988 Oct 31; 60(2):193-8. PubMed ID: 2851191
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D, Walenga JM, Fareed J, Bick RL.
    Hematol Oncol Clin North Am; 2003 Feb 31; 17(1):313-41. PubMed ID: 12627673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.